Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6916-6923

  Biagi, Ettore ^a,d   Rousseau, Raphael ^a   Yvon, Eric ^a   Schwartz, Mary ^b   Dotti, Gianpietro ^a   Foster, Aaron ^a   Havlik Cooper, Diana ^a   Grilley, Bambi ^a   Gee, Adrian ^a   Baker, Kelty ^a   Carrum, George ^a   Rice, Lawrence ^a   Andreeff, Michael ^c   Popat, Uday ^a   Brenner, Malcolm ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; PROTEIN LAG 3; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; B CELL LEUKEMIA; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INJECTION PAIN; INJECTION SITE REACTION; LYMPH NODE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION;

AGED; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE SYSTEM; INTERLEUKIN-2; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 26444566785     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0484     Document Type: Article

References (37)

1. Dilloo D, Brown M, Roskrow M, et al. CD40 ligand induces an antileukemia immune response in vivo. Blood 1997;90:1927-33.
2. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998;101:1133-41.
3. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-24.
4. Takahashi S, Rousseau R, Yotnda P, et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 2001;12:659-70.
5. Takahashi S, Rousseau R, Yotnda P, et al. Transgenic expression of CD40L and IL-2 induces an autologous immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001;8:378-87.
6. McLellan AD, Sorg RV, Williams LA, Hart DN. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway. Eur J Immunol 1996;26:1204-10.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
8. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998;393: 478-80.
9. Fujita N, Kagamu H, Yoshizawa H, et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) Tcells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 2001;167:5678-88.
10. Grossmann ME, Brown MP, Brenner MK. Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther 1997;8:1935-43.
11. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by upregulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-80.
12. Cardoso AA, Seamon MJ, Afonso HM, et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 1997;90:549-61.
13. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999;93: 1992-2002.
14. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 2002;62:3195-9.
15. Dotti G, Savoldo B, Yotnda P, Donna R, Brenner M. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood 2002;100:200-7.
16. Biagi E, Yvon E, Dotti G, et al. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther 2003;14:545-59.
17. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature 1970; 227:168-70.
18. Biagi E, Dotti G, Yvon E, et al. Molecular transfer of CD40 and 0X40 ligands to leukemic human B-cells induces expansion of autologous tumor-reactive cytotoxic T-lymphocytes. Blood 2005;105: 2436-42.
19. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101:1718-26.
20. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21:503-13.
21. + derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005;105:750-8.
22. Yvon ES, Vigouroux S, Rousseau RF, et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood 2003;102:3815-21.
23. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
24. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004;16: 157-62.
25. Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004;64:6827-30.
26. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood 2004;104:26-33.
27. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:3854-9.
28. Castro JE, Cantwell MJ, Prussak CE, Bole J, Wierda WJ, Kipps TJ. Long-term follow up of chronic lymphocytic leukemia patients treated with CD40-ligand (CD154) gene therapy [abstract]. Blood 2003; 102:491a.
29. Roskrow MA, Dilloo D, Suzuki N. Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res 1999;23:549-57.
30. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 2003;63:4497-506.
31. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9.
32. Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma 2002;43:881-4.
33. Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:5-21.
34. Orsini E, Guarini A, Foa R. Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000;4:73-98.
35. high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005 May 24. Epub ahead of print.
36. + regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004;13:613-20.
37. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53: 73-8.